AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

AstraZeneca’s Enhertu (trastuzumab deruxtecan) emerged as the highest-selling new drug in India in 2024, generating Rs 58 ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Stephens Inc. AR lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.2% in the fourth quarter, Holdings Channel reports. The fund owned 24,987 shares of the company’s ...